Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease

Kopp, Aude; Mangin, O.; Gantzer, Laurène; Lekens, B.; Simoneau, Guy G.; Ravelomanantsoa, Manoro; Evans, John; Bergmann, Jean‐François; Sellier, Pierre

doi:10.1080/21645515.2020.1756669

Cited by 20 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for the influenza vaccine, pneumococcal vaccine uptake was overestimated in our study compared with the findings of a large national survey conducted in France using national panels of medical records of 2000 GPs and 1000 specialist practitioners in ambulatory care (4%) [9], with nearly 100,000 individuals with chronic conditions in UK (32%) [18] or with nearly 200,000 immunocompromised in Germany (2% to 7%) [19].…”

Section: The Vaccine Uptake In France and Europe And Associated Factorscontrasting

confidence: 74%

See 1 more Smart Citation

Patients’ Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections

Loubet

Rouviere

Merceron³

et al. 2021

Vaccines

View full text Add to dashboard Cite

Introduction: The objective of our study was to assess, in an at-risk population, perception and knowledge about influenza and pneumococcal vaccinations. Methods: An anonymous web-based survey was submitted to patients recruited in France, from both an Ipsos internal panel and AVNIR patient associations. The study was conducted between July and October 2020, in the context of the COVID-19 pandemic. Results: Overall, 2177 questionnaires from patients at risk of infection were analyzed. Almost all respondents (86%, 1869/2177) declared themselves to be favorable to vaccination. Nearly half of the patients (49%, 1069/2177) were aware of which vaccine was recommended for their specific situation. This percentage was significantly (p < 0.001) higher for members of a patient association and for people affected by multiple chronic conditions and varied according to the type of condition. Almost two-thirds of patients (1373/2177) declared having been vaccinated during the 2019/2020 influenza season, and 41% (894/2177) were certain about being up to date with the pneumococcal vaccination. The main barriers to vaccination for influenza are the fear of side effects, doubt regarding the efficacy of the vaccine and for pneumococcal vaccination, and the absence of suggestions by the healthcare professionals (HCPs), as 64% of respondents were not recommended to obtain pneumococcal vaccination. To improve vaccine coverage, information is of prime importance and GPs are recognized as the main HCP to inform about vaccination. Nearly two-thirds (62%, 1360/2177) of patients declared that the COVID-19 pandemic convinced them to have all the recommended vaccines. Conclusion: Our study highlighted the nonoptimal vaccine coverage in at-risk populations despite a highly positive perception of vaccines and confirmed that physicians are on the front lines to suggest and recommend these vaccinations, especially in the current pandemic context, which may be used to promote other vaccines.

show abstract

Section: The Vaccine Uptake In France and Europe And Associated Factorscontrasting

confidence: 74%

“…Previous surveys have identified the French population's reluctance regarding vaccination and low vaccination coverage, especially among at-risk patients, despite these recommendations [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Patients’ Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections

Loubet

Rouviere

Merceron³

et al. 2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…Despite the efforts of primary care providers and public health agencies, vaccine coverage has remained far below the expected coverage rate [ 6 , 7 ]. The most common barriers to vaccination include a perceived lack of safety, a deficit of awareness, complacency (i.e., doubts about the necessity of vaccines), and vaccine misconceptions [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of a Multifaceted Informational-Based and Text Message Reminders on Pneumococcal and Influenza Vaccinations in Hospital Emergency Departments: A Cluster-Randomized Controlled Trial

et al. 2021

View full text Add to dashboard Cite

Objectives. We aimed to evaluate the effectiveness of a multifaceted procedure in improving pneumococcal and influenza vaccinations 6 months after an emergency department (ED) visit among patients aged 65 years and older. Methods. We conducted a cluster-randomized, controlled, parallel-group, open-label implementation trial in 18 EDs in France and Monaco. Participants were recruited from November 2015 to September 2016. EDs were randomly assigned with a 1:1 ratio to provide either a multifaceted procedure that combined structured information about pneumococcal and influenza vaccines and three text message reminders sent to patients every two weeks (intervention arm) or nonstructured information only (control arm). The outcomes were self-reported pneumococcal vaccination and influenza vaccination rates within 6 months of enrollment. Results. A total of 9 EDs were randomized to the intervention arm (n = 780 patients) and 9 to the control arm (n = 695 patients). The median age for all enrolled patients was 74 years (25–75th percentiles, 69 to 82): 50.1% were male, 34.9% had at least one underlying condition, and 30.7% were at risk for invasive pneumococcal infection. In the intention-to-treat analysis, the multifaceted intervention did not alter the pneumococcal vaccination rate (6.4% versus 4.6%, absolute difference: 1.8; 95% CI: [−0.9 to 4.4]; p = 0.19), whereas it improved the influenza vaccination rate (52.1% versus 40.0%, absolute difference: 12.1; 95% CI: [2.4 to 21.8]; p = 0.01). At 12 months, mortality did not differ between the intervention (9.7%) and control (11.2%) arms (p = 0.35). Conclusions. A multifaceted intervention based on text message reminders provides an opportunity to increase anti-influenza vaccination among elderly patients visiting the ED. Efforts are warranted to provide better information on pneumococcal diseases and the benefits of pneumococcal vaccines, especially in the elderly.

show abstract

“…Vaccination coverage in adults in France is extremely low (between 5% and 20%) and varies considerably between the different risk groups [ 8 ]. As the risk of pneumococcal diseases is very high in adults aged ≥65 years, this represents a significant loss of opportunity.…”

Section: Introductionmentioning

confidence: 99%

“…As the risk of pneumococcal diseases is very high in adults aged ≥65 years, this represents a significant loss of opportunity. A number of factors may contribute to this unsatisfactory situation [ 8 ]. Firstly, identifying patients eligible for vaccination is not straightforward, since different comorbidities may be managed by different specialists or general practitioners.…”

Section: Introductionmentioning

confidence: 99%

The Health Professional’s View on the Inclusion of Age in the Recommendations for Pneumococcal Vaccination: Results of a Cross-Sectional Survey in France

Farge¹,

Wazières

Raude

et al. 2021

Geriatrics

View full text Add to dashboard Cite

Elderly people are at high risk for pneumococcal infections. However, older age is not an eligibility factor for pneumococcal vaccination in France. Adults with certain co-morbidities or immunocompromised states are eligible for vaccination, which leaves adults aged ≥65 years without comorbidities at-risk for pneumococcal infections. The objective of the study was to evaluate the acceptability to healthcare professionals (HCPs) of extending pneumococcal vaccination to all individuals ≥65 years. Based on themes identified in semi-structured interviews with 24 HCPs, a representative sample of 500 general practitioners and pharmacists were surveyed about their knowledge, attitudes and beliefs with respect to pneumococcal vaccination for individuals ≥65 years. Current recommendations for pneumococcal vaccination are poorly understood by participants (mean score: 5.8/10). Respondents were generally supportive of inclusion of age in vaccination recommendations (7.5/10), with 58% being very supportive. For 72% of HCPs, this would contribute to improved vaccination coverage. The strategy could be facilitated by associating pneumococcal vaccination with the influenza vaccination campaign (8.3/10). Pharmacists were favourable to participating in pneumococcal vaccination (8.5/10). In conclusion, extension of pneumococcal vaccination to all people aged ≥65 years would be welcomed by HCPs, simplifying identification of patients to be vaccinated and potentially improving vaccination coverage.

show abstract

Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease

Cited by 20 publications

References 26 publications

Patients’ Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections

Patients’ Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections

Effectiveness of a Multifaceted Informational-Based and Text Message Reminders on Pneumococcal and Influenza Vaccinations in Hospital Emergency Departments: A Cluster-Randomized Controlled Trial

The Health Professional’s View on the Inclusion of Age in the Recommendations for Pneumococcal Vaccination: Results of a Cross-Sectional Survey in France

Contact Info

Product

Resources

About